Sonic Articles & Analysis
16 news found
Shockwave aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). ...
Shockwave aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). ...
Shockwave aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). ...
Shockwave aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). ...
Shockwave aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). ...
Shockwave aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). ...
Shockwave aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). ...
“Our vision at Nimbus is to improve health through Canadian-led innovation and by investing in this technology spun-out of the University of British Columbia, we are helping solve real-world health crises like chronic liver disease.” About Sonic Incytes Medical Corp. Sonic Incytes believes in creating accessible and affordable diagnostic solutions ...
” Sonic Incytes’ poster presentation will be available to conference registrants through the online AASLD portal on November 12, and will be available subsequently on the Sonic Incytes’ website at https://www.sonicincytes.com/physicians/#research. ...
HistoSonics announced today that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its new therapy platform. Histotripsy of the liver provides clinicians the first automated external beam therapy using acoustic energy to mechanically destroy and liquefy tissue in the liver without incisions, ionizing radiation or heat. “The ...
It takes about five minutes and can be performed in a physician’s office. About Sonic Incytes Medical Corp. Sonic Incytes believes in creating accessible and affordable diagnostic solutions – with health insights you can count on – to improve patient care. Recognizing the rise of chronic liver disease, Sonic Incytes has made it ...
MedTech Innovator’s 2021 top 20 Asia Pacific Accelerator companies include: Active Needle – Abingdon, United Kingdom Adiuvo Diagnostics – Chennai, India Biorithm – Singapore BrainSightAI – Bangalore, India Huinno – Seoul, South Korea MedCorp Technologies – Hawthorn, Australia Miraqules – Bhubaneswar, India Navi Medical Technologies – ...
Visit our in-person booth for live demos of Velacur, the first handheld 3D liver health assessment solution. Developed by Sonic Incytes Medical Corp., VelacurTM is a breakthrough, point of care ultrasound solution that is redefining the standard of care for chronic liver disease. ...
Recognized for its growth potential, Sonic Incytes Medical Corp. has been named a top technology company in the 19th Annual “Ready to Rocket” list published by Rocket Builders. ...
HistoSonics announced today the treatment of the first patient in the #HOPE4LIVER US Study. The investigational device study was approved by the FDA in the fourth quarter of 2020. The study is designed to evaluate the safety and efficacy of the company’s platform technology, which uses the novel science of histotripsy, a form of therapeutic focused ultrasound, to mechanically destroy ...
We also have controlled release of Klotho, sonic hedgehog SDF-1, PDGF and follistatin. All of which, when appropriately used, can increase the health of any smooth muscle in the body. ...